Innovent Biologics Inc (1801) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Innovent Biologics Inc stock HK$50.92, price HK$84.75, that is 39.9% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Innovent Biologics Inc
1801 · HKFar too expensive (fair value 40% below the price), but solid company and rising price: meets 2 of 3 rules.
Main risks:
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range HK$18.64 – HK$109.80 · fair‑value band HK$35.64 – HK$66.20 · the HK$84.75 price screens above the HK$50.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Innovent Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally.
Show moreShow less
The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.
Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection).
In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Stock analysis
Innovent Biologics Inc (1801) currently trades at HK$84.75, while our model-based Fair Value estimate is HK$50.92, 40% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$229.26 per share, and 5 of the 23 models we run sit above the HK$84.75 price.
Bear case: the Economic Profit group reads lowest at HK$14.84, and 18 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: HK$35.64 (bear) to HK$66.20 (bull), the price of HK$84.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Innovent Biologics Inc reported revenue of 13.0B CNY in FY2025 versus 4.3B CNY in FY2021, a compound +32.2%/yr. Reported net income was 814M CNY in FY2025.
Key figures
Market cap HK$153B (≈ $19.5B) Large · P/E ratio 110.1 · P/S ratio 6.87 · Net margin 6.2% · Return on equity 7.0% · Return on assets (EBIT) −9.2% (5-year average) · Operating margin 14.0% · Revenue (TTM) 15.7B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −40%, 1801 screens richer than that median.
Fair Value models
All 23 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Recent news
- Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hy
- Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
- 2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Compare Innovent Biologics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 1801 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 1801 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 1801 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 1801 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 1801 |
| BeOne Medicines AG 6160 | HK$249.80 | HK$152.92 | −39% | vs 1801 |
| Moderna, Inc MRNA | $223.37 | $135.64 | −39% | vs 1801 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 1801 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 1801 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 1801 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Innovent Biologics Inc (1801) overvalued or undervalued?
What is the fair value of 1801?
What is the quality score of 1801?
What is the price target for Innovent Biologics Inc (1801)?
What is the Innovent Biologics Inc stock forecast for 2026?
What is the revenue of Innovent Biologics Inc (1801)?
What growth is priced into Innovent Biologics Inc (1801)?
What discount rate (WACC) does the fair value of 1801 use?
What is a reverse DCF?
How much growth has Innovent Biologics Inc (1801) delivered so far?
How fast is the sector of Innovent Biologics Inc (1801) growing?
What is the free cash flow yield of Innovent Biologics Inc (1801)?
What is the intrinsic value of Innovent Biologics Inc (1801)?
Is Innovent Biologics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 1801?
How much is Innovent Biologics Inc worth?
What do the bullish and bearish scenarios say about 1801?
What is the P/E ratio of 1801?
What is the PEG ratio of 1801?
How solid is the balance sheet of Innovent Biologics Inc (1801)?
How far is 1801 from its 52-week high?
Which stocks are comparable to Innovent Biologics Inc?
Is Innovent Biologics Inc stock attractive at the current price?
How is the fair value of 1801 calculated?
Is it still worth investing in stocks now?
What is the share price of Innovent Biologics Inc (1801)?
What should I pay attention to with Innovent Biologics Inc right now?
Key figures of Innovent Biologics Inc
How large is the market capitalisation of Innovent Biologics Inc (1801)?
What is the P/S ratio of Innovent Biologics Inc (1801)?
What is the net margin of Innovent Biologics Inc (1801)?
What is the return on equity of Innovent Biologics Inc (1801)?
What is the EBIT return on assets of Innovent Biologics Inc (1801)?
What is the operating margin of Innovent Biologics Inc (1801)?
How fast is revenue growing at Innovent Biologics Inc (1801)?
How fast are earnings growing at Innovent Biologics Inc (1801)?
How much net cash does Innovent Biologics Inc (1801) hold?
Watch Innovent Biologics Inc in the live analysis
One click puts Innovent Biologics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.